AU2001253065A1 - Compositions and methods for treating hair loss using oximyl- and hydroxylamino-prostaglandins - Google Patents

Compositions and methods for treating hair loss using oximyl- and hydroxylamino-prostaglandins

Info

Publication number
AU2001253065A1
AU2001253065A1 AU2001253065A AU5306501A AU2001253065A1 AU 2001253065 A1 AU2001253065 A1 AU 2001253065A1 AU 2001253065 A AU2001253065 A AU 2001253065A AU 5306501 A AU5306501 A AU 5306501A AU 2001253065 A1 AU2001253065 A1 AU 2001253065A1
Authority
AU
Australia
Prior art keywords
oximyl
hydroxylamino
prostaglandins
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253065A
Inventor
Mitchell Anthony Delong
John Mcmillan Mciver
Robert Scott Youngquist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of AU2001253065A1 publication Critical patent/AU2001253065A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
AU2001253065A 2000-03-31 2001-03-30 Compositions and methods for treating hair loss using oximyl- and hydroxylamino-prostaglandins Abandoned AU2001253065A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19384400P 2000-03-31 2000-03-31
US60193844 2000-03-31
PCT/US2001/010547 WO2001074307A2 (en) 2000-03-31 2001-03-30 Compositions and methods for treating hair loss using oximyl- and hydroxylamino- prostaglandins

Publications (1)

Publication Number Publication Date
AU2001253065A1 true AU2001253065A1 (en) 2001-10-15

Family

ID=22715247

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253065A Abandoned AU2001253065A1 (en) 2000-03-31 2001-03-30 Compositions and methods for treating hair loss using oximyl- and hydroxylamino-prostaglandins

Country Status (7)

Country Link
US (2) US20020146439A1 (en)
EP (1) EP1267808A2 (en)
JP (1) JP2003528895A (en)
CN (1) CN1221238C (en)
AU (1) AU2001253065A1 (en)
CA (1) CA2401269A1 (en)
WO (1) WO2001074307A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766163B2 (en) 1999-03-05 2003-10-09 Duke University C16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
AU2001265151A1 (en) * 2000-05-31 2001-12-11 Encelle, Inc. Method of stimulating hair growth
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
TWI495471B (en) * 2003-08-12 2015-08-11 R Tech Ueno Ltd Composition and method for promoting hair growth
EP1727516B1 (en) 2004-03-26 2014-05-14 DSM IP Assets B.V. Composition comprising an hdac inhibitor in combination with a retinoid
KR100873664B1 (en) 2004-04-28 2008-12-11 코스모세키유 가부시키가이샤 Hair restorer
WO2006029818A2 (en) * 2004-09-16 2006-03-23 Dsm Ip Assets B.V. Cosmetic compositions containing an hydroxamic acid compound optionally in combination with a retinoid
US20060135609A1 (en) * 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
EP2136773A2 (en) * 2007-03-20 2009-12-30 The Procter & Gamble Compositions containing amine oxide surfactants or soil penetration agents
WO2009004873A1 (en) * 2007-06-29 2009-01-08 Taisho Pharmaceutical Co., Ltd. Prostaglandin derivative-containing aqueous liquid agent
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
FR2920309B1 (en) 2007-08-28 2010-05-28 Galderma Res & Dev USE OF TRAVOPROST TO TREAT THE FALL OF HAIR
AU2009246330B2 (en) * 2008-05-14 2015-04-02 Peter Thomas Roth Labs, Llc Prostaglandin based compositions and method of use thereof
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010064203A1 (en) 2008-12-02 2010-06-10 L'oreal Combination of reduced glutathione and amino acids for improving the quality of the hair in women
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
FR2949052B1 (en) 2009-08-13 2015-03-27 Oreal PROCESS FOR COSMETIC TREATMENT OF SCALP.
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
WO2011057129A2 (en) 2009-11-09 2011-05-12 Allergan, Inc. Compositions and methods for stimulating hair growth
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
WO2015065716A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
PT2838533T (en) 2012-04-16 2017-11-22 Univ Texas Compositions and methods of modulating 15-pgdh activity
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
JP2020514323A (en) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ Compositions and methods for modulating short chain dehydrogenase activity
EA202191422A1 (en) 2018-11-21 2021-10-21 Кейс Вестерн Ризерв Юниверсити COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF SHORT RENAL DEHYDROGENASE
PE20230777A1 (en) 2020-05-20 2023-05-09 Rodeo Therapeutics Corp COMPOSITIONS AND METHODS TO MODULATE THE ACTIVITY OF SHORT CHAIN DEHYDROGENASES

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US13294A (en) * 1855-07-17 Improved apparatus for cooling repeating fire-arms
US37913A (en) * 1863-03-17 Improvement in sewing-machines
US37914A (en) * 1863-03-17 Improved automatic nose-bag
US146439A (en) * 1874-01-13 Improvement in pruning-shears
US730967A (en) * 1897-02-27 1903-06-16 Gen Electric Dynamo-electric machine.
US3461461A (en) * 1965-11-01 1969-08-12 Upjohn Co 6-amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidines
US3435053A (en) * 1966-06-06 1969-03-25 Upjohn Co Cyclopenta(b)pyrans
US3636120A (en) * 1967-10-09 1972-01-18 Upjohn Co Prostaglandin e primary alcohols
BE755555A (en) * 1969-09-02 1971-03-01 Richardson Merrell Inc QUINOXALINE DERIVATIVES
BE791369A (en) * 1971-11-16 1973-05-14 American Cyanamid Co TRIS- (META-HYDROXYBENZYL) CYANURATES SUBJECT TO STERIC PREVENTION AND USE AS ANTI-OXIDANTS
US3798275A (en) * 1972-04-05 1974-03-19 Ciba Geigy Corp Etherified mercapto-methoxyamines
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
US3882245A (en) * 1972-11-01 1975-05-06 Upjohn Co Use of prostaglandins in combating shock
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
US4152527A (en) * 1972-11-08 1979-05-01 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
JPS5720305B2 (en) * 1973-02-28 1982-04-27
DE2365101A1 (en) * 1973-12-21 1975-07-10 Schering Ag NEW PROSTANIC ACID DERIVATIVES AND METHOD FOR THEIR PRODUCTION
US3934013A (en) * 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition
US4217360A (en) * 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
GB1506817A (en) * 1975-03-31 1978-04-12 Upjohn Co Prostaglandins
DE2517771A1 (en) * 1975-04-18 1976-10-28 Schering Ag NEW PROSTAGLANDIN ACETYLENE ANALOGS AND METHOD FOR THEIR PRODUCTION
GB1520522A (en) * 1975-06-16 1978-08-09 Ono Pharmaceutical Co 16-methyleneprostaglandins
US4158667A (en) * 1976-02-04 1979-06-19 The Upjohn Company 6-Keto PGF analogs
US4596812A (en) * 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4268522A (en) * 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
US4499293A (en) * 1976-09-22 1985-02-12 The Upjohn Company PGI2 Salts
US4089885A (en) * 1976-11-05 1978-05-16 American Home Products Corporation Prostaglandin derivatives
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4206151A (en) * 1978-12-21 1980-06-03 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
JPS61126069A (en) * 1984-11-21 1986-06-13 Res Dev Corp Of Japan Prostaglandin derivative
US5863948A (en) * 1985-06-14 1999-01-26 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US4889845A (en) * 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US5591887A (en) * 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
DE3876050T2 (en) * 1987-09-18 1993-03-25 R Tech Ueno Ltd OCULAR HYPOTENSIVAGENTS.
ATE101342T1 (en) * 1988-09-06 1994-02-15 Kabi Pharmacia Ab PROSTAGLAND INDIVIDUALS FOR THE TREATMENT OF GREEN STAR OR OCULAR HYPERTENSION.
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (en) * 1990-04-04 1995-06-11 Aderk Ueno Kk
US5302617A (en) * 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
US5312832A (en) * 1991-05-17 1994-05-17 Allergan, Inc. Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5641494A (en) * 1992-03-20 1997-06-24 Janssen Pharmaceutica N.V. Agent for regulating the greasiness of the skin
US5578643A (en) * 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
JP3102141B2 (en) * 1992-05-29 2000-10-23 東レ株式会社 Hair restorer
US5817694A (en) * 1992-06-08 1998-10-06 New Pharma International Corp. 16-methyl-11,16-dihydroxy-9-oxoprost-2,13-dien-1-oic acid and derivatives
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
JP3002258B2 (en) * 1992-10-13 2000-01-24 アルコン ラボラトリーズ， インコーポレイテッド Combination of prostaglandin and clonidine derivatives for the treatment of glaucoma
US5395932A (en) * 1993-04-30 1995-03-07 G. D. Searle & Co. 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5985597A (en) * 1993-05-26 1999-11-16 Merck Frosst Canada, Inc. DNA encoding prostaglandin receptor EP1
US5869281A (en) * 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5516652A (en) * 1993-10-06 1996-05-14 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor IP
SE9303627D0 (en) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for the prevention of cataract
CA2179399A1 (en) * 1993-12-20 1995-06-29 Kiyoshi Taniguchi 4,5-diaryloxazole derivatives
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US5458883A (en) * 1994-01-12 1995-10-17 Duke University Method of treating disorders of the eye
SE9403158D0 (en) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US5885974A (en) * 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
WO1996020925A1 (en) * 1995-01-06 1996-07-11 Toray Industries, Inc. Benzene-fused heterocyclic derivative and use of the same
US5885766A (en) * 1995-02-17 1999-03-23 Societe L'oreal S.A. Method of screening of substances for their effect on the expression of mediators of inflammation in a hair follicle
AU7672096A (en) * 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
HUP9601442A3 (en) * 1995-07-25 1999-03-29 Panacea Biotec Ltd Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them
CA2236582C (en) * 1995-12-22 2004-08-17 Alcon Laboratories, Inc. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
JPH10265454A (en) * 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd 3,7dithiaprostanoic acid derivative, its production and medicine containing the same derivative as active ingredient
WO1998033497A1 (en) * 1997-02-04 1998-08-06 Johnstone Murray A Method of enhancing hair growth
US6030959A (en) * 1997-04-04 2000-02-29 Monsanto Company Gastro-specific prodrugs
EP1007028A4 (en) * 1997-05-09 2002-06-05 8-iso-prostaglandins for glaucoma therapy
JP4619531B2 (en) * 1997-09-09 2011-01-26 デューク ユニバーシティ Aromatic C16-C20 substituted tetrahydroprostaglandins useful as FP agonists
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
AU1709699A (en) * 1997-12-22 1999-07-12 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
CA2324343C (en) * 1998-03-31 2005-05-31 The Procter & Gamble Company C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
WO2001010873A1 (en) * 1999-08-04 2001-02-15 The Procter & Gamble Company Novel 2-decarboxy-2-phosphinico prostaglandin f analogs
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US6548535B2 (en) * 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
EP1186287A1 (en) * 2000-03-31 2002-03-13 Toray Industries, Inc. Hair growth or hair formation controlling agents
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
FR2812190B1 (en) * 2000-07-28 2003-01-31 Oreal USE OF NON-PROSTANOIC AGONISTS OF EP-2 AND / OR EP-4 PROSTAGLANDIN RECEPTORS AS A COSMETIC AGENT FOR MITIGATING, DECREASING OR STOPPING HAIR AND HAIR LOSS
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20050058614A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US20060135609A1 (en) * 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins

Also Published As

Publication number Publication date
CN1221238C (en) 2005-10-05
CA2401269A1 (en) 2001-10-11
EP1267808A2 (en) 2003-01-02
WO2001074307A3 (en) 2002-04-11
WO2001074307A2 (en) 2001-10-11
CN1419439A (en) 2003-05-21
JP2003528895A (en) 2003-09-30
US20060121069A1 (en) 2006-06-08
US20020146439A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
AU2001253065A1 (en) Compositions and methods for treating hair loss using oximyl- and hydroxylamino-prostaglandins
AU2001245437A1 (en) Lightweight methods and compositions for well treating
EP1066018B8 (en) Hair treatment compositions
AU2002308671A1 (en) Method and compositions for coloring hair
AU2001249361A1 (en) Stable alkaline hair bleaching compositions and method for use thereof
AU2778801A (en) Antisense compositions and methods
AU1215501A (en) Hair coloring compositions and methods
EP1438062A4 (en) Methods and compositions for treating dermal lesions
AU2001243210A1 (en) Pretreatment for hair coloring compositions and methods
AU2271400A (en) Composition, kit, method and device for hair treatment
AU2002236626A1 (en) Compositions and methods for treating hyperpigmentation
AU7311501A (en) Cosmetic composition and method
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU2002345353A1 (en) Methods and compositions that affect melanogenesis (pfi-016cip/pct)
AU1702301A (en) Hair treatment composition
AU5647601A (en) Hair treatment compositions
AU2001273972A1 (en) Hair treatment composition
AU2002221796A1 (en) Hair clip and method for using said hair clip
AU3205801A (en) Method and composition for promoting hair growth
AU2001233932A1 (en) Method and composition
AU3204899A (en) Hair treatment composition and method
AU2001218024A1 (en) Methods for treating and preventing alopecia
AU5974999A (en) Hair treatment composition, method and use
AU2001238179A1 (en) Method and compositions for treating hepatocellular cancer
AU2002239775A1 (en) Chemical-library composition and method